RPX Corporation (Nasdaq:RPXC) is a leading provider of patent risk solutions, offering defensive buying, acquisition syndication, patent intelligence and advisory services. Since its founding in 2008, RPX has introduced efficiency to the patent market by providing a rational alternative to litigation.

RPX Corporation, a leading provider of patent risk solutions, offering defensive buying, acquisition syndications, patent intelligence and advisory services, yesterday announced its financial results for the fourth quarter and year ended December 31, 2011. Revenue for the fourth quarter of 2011 increased 43% to $42.4 million, compared to $29.7 million in the fourth quarter of 2010. For fiscal year 2011, revenue was $154.0 million, compared to revenue of $94.9 million for fiscal year 2010.

Net acquisition spend during the quarter totaled $28.7 million, and included nine new acquisitions of patent assets, in addition to the exercise of previously negotiated options to acquire licenses for new members. The net book value of RPX’s portfolio of patent assets increased to $163.4 million as of December 31, 2011 from $153.0 million as of September 30, 2011.

GAAP net income for the quarter was $6.9 million or $0.13 per diluted share, compared to $3.9 million or $0.07 per diluted share in the fourth quarter of 2010. On a pro forma basis giving effect to the restricted stock outstanding and the conversion of all preferred shares into common shares at the beginning of the period, net income was $0.13 per pro forma diluted share in the fourth quarter of 2011, compared to $0.10 per pro forma diluted share in the prior year period. For fiscal 2011, GAAP net income was $29.1 million or $0.57 per diluted share, compared to $13.9 million or $0.23 per diluted share for fiscal 2010. On a pro forma basis, net income was $0.60 per pro forma diluted share for fiscal 2011, compared to $0.36 per pro forma diluted share in the prior year.

For more information about RPX Corporation, please visit www.rpxcorp.com

**************************************************

Insulet Corporation (NASDAQ:PODD), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, announced financial results for the fourth quarter and full year ended December 31, 2011. Fourth quarter 2011 revenue increased 70% to $47.2 million, compared to $27.8 million in the fourth quarter of 2010. Gross profit for the fourth quarter of 2011 improved by 45% to $20.1 million, as compared to a gross profit of $13.8 million, for the fourth quarter of 2010. Operating loss for the fourth quarter of 2011 was $10.5 million, compared to an operating loss of $9.7 million in the fourth quarter of 2010. The increase in the operating loss is a result of an increase in operating expenses including the amortization of acquired intangible assets related to the acquisition of Neighborhood Diabetes.

Insulet Corporation, a medical device company, engages in the development, manufacture, and marketing of insulin infusion systems for people with insulin-dependent diabetes in the United States.

**************************************************

Gamco Investors, Inc. (NYSE:GBL) announced fourth quarter 2011 earnings of $23.7 million or $0.89 per fully diluted share versus $26.9 million or $0.99 per fully diluted share in the fourth quarter 2010. Revenues were $85.0 million in the fourth quarter of 2011, down $10.4 million, or 10.9%, from $95.4 million in the prior year quarter. Incentive fees for the fourth quarter of 2011 were $9.0 million vs. $24.6 million in the fourth quarter of 2010. Revenues, excluding incentive fees, rose $5.2 million. Operating income before management fee was $35.5 million, a 3.8% increase from $34.2 million in the prior year period. Operating margin before management fee increased to 41.8% in the 2011 fourth quarter versus 35.8% in the 2010 fourth quarter.

GAMCO Investors, Inc. is a publicly owned holding investment manager. The firm also provides wealth management, investment advisory, institutional research, brokerage, dealer, underwriting, and distribution services to its clients.

**************************************************

Amicus Therapeutics, Inc. (Nasdaq:FOLD) announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview at the Leerink Swann 2012 Global Healthcare Conference in New York, NY on Wednesday, February 15 at 3:30 p.m. ET. A live webcast of the presentation can be accessed through the Investors section of the Amicus Therapeutics corporate web site at http://ir.amicustherapeutics.com/events.cfm, and will be archived for 90 days. Participants are encouraged to visit the web site 10 minutes prior to the start of the presentation to register, download and install any necessary software.

Amicus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally-administered, small molecule drugs for the treatment of various human genetic diseases.

*******************************************
Sign-Up For Free Hot Stock Alerts At http://stockhottips.com/signup

*******************************************
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. StockHotTips.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer (http://stockhottips.com/disclaimer)is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold StockHotTips.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

American Video Teleconferencing AVOT.PK biotechnology Canada cancer Cleantech Transit CLNO consulting organization Crown Equity CROWN EQUITY HOLDINGS Crown Equity Holdings Inc. crwe crwe.ob crwenewswire CRWE Newswire eco friendly GOLD gold mining greenhouse greenhouse holdings Health hot news hot stock hot stocks Inc. Ken Bosket mineral exploration Mining nasdaq National Health Partners NHPR NuroPro nyse orfg.pk orofino gold Otc.bb otc:crwe otc:pwrm PINK:ORFG Power3 Medical Products pwrm pwrm.ob StockHotTips Stock Hot Tips warren buffet